Brainstorm cell therapeutics announces full year 2021 financial results and provides a corporate update

New york, march 28, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the fiscal year ended december 31, 2021 and provided a corporate update.     "we began 2022 with strong momentum and phase 3 data showing that nurown® appears to deliver meaningful clinical benefits to als patients with less advanced disease," said chaim lebovits, chief executive officer.
BCLI Ratings Summary
BCLI Quant Ranking